Calypte Biomedical Launches Calypte Life Sciences Product Line
Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, today announced the launch of a new product line, Calypte Life Sciences. Calypte Life Sciences offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers and institutions seeking to develop and optimize immunodiagnostic assay systems. Calypte Life Sciences products are being distributed through a new on-line catalog (www.calyptelifesciences.com) as well as through Calypte’s established worldwide network of distributors.
Roger I. Gale, Calypte’s President and Chief Executive Officer, stated, “Calypte Life Sciences is a natural extension of what we already do and an important addition to our business, representing another potential revenue stream. Research & Development is one of the strengths of Calypte. We have, among our scientists, a tremendous reservoir of knowledge and experience and they are continuously coming up with novel approaches to solving some very difficult problems commonly encountered by assay developers. The Life Sciences catalog provides a further means by which we can capitalize on our R&D investment and bring new products to market quite quickly. Our Life Sciences division will serve the needs of a large and diverse group of customers that includes universities, governmental organizations, and private companies focusing primarily on assay development. It is particularly exciting that a significant portion of the market is based right here in the U.S.”
Dr. Ronald Mink, Calypte’s Chief Science Officer, stated that, “The products featured in our Life Sciences catalog are based mostly on technologies that we developed for our core diagnostics business. Many are truly unique. Our Gold Conjugate Clearant, which is currently featured on the home page of our on-line catalog, is one example of such a technology. It helps to reduce the amount of background color ‘noise’ on membrane-based rapid tests thereby improving their clinical performance. This is just one example and we have many more unique products that can help to improve the performance of diagnostic assays of all types. Through our Life Sciences catalog we are making these products broadly available to researchers and creating additional opportunities for developing better, faster and more cost effective diagnostic products.”
Christopher P. Kafka, Vice President of Business Development, stated, “We have been testing the market to evaluate our products and to receive feedback on our new on-line catalog. I am happy to say that the response we have received leading up to our formal launch has been very positive. We have already seen our first sales and in the coming months we plan to aggressively promote our new Life Sciences offerings at major conferences such as the general meeting of the American Society for Microbiology (ASM) in early June, and the annual meeting of the American Association for Clinical Chemistry (AACC) in late July, as well as through online and print media.”
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by managements. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2007 and relate to our ability to obtain sufficient financing, if and as needed, and access funds from our existing financing arrangements, in order to continue our current and future operations, and whether demand for our test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. We assume no obligation to, and do not currently intend to, update these forward-looking statements.